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Fat and muscle lipolysis involves functional interac-
tions of adipose triglyceride lipase (ATGL), a-b hy-
drolase domain-containing protein 5 (ABHD5), and
tissue-specific perilipins 1 and 5 (PLIN1 and PLIN5).
ABHD5 potently activates ATGL, but this lipase-pro-
moting activity is suppressed when ABHD5 is bound
to PLIN proteins on lipid droplets. In adipocytes, pro-
tein kinase A (PKA) phosphorylation of PLIN1 rapidly
releases ABHD5 to activate ATGL, but mechanisms
for rapid regulation of PLIN5-ABHD5 interaction in
muscle are unknown. Here, we identify synthetic
ligands that release ABHD5 from PLIN1 or PLIN5
without PKA activation and rapidly activate adipo-
cyte and muscle lipolysis. Molecular imaging and
affinity probe labeling demonstrated that ABHD5 is
directly targeted by these synthetic ligands and addi-
tionally revealed that ABHD5-PLIN interactions are
regulated by endogenous ligands, including long-
chain acyl-CoA. Our results reveal a new locus of
lipolysis control and suggest ABHD5 ligands might
be developed into novel therapeutics that directly
promote fat catabolism.
INTRODUCTION
The storage and mobilization of lipid energy are fundamental
processes of virtually all eukaryotic cells. Mobilization of fatty
acids from stored triacylglycerol occurs on the surface of intra-
cellular lipid droplets (LDs) and is thought to be controlled by
the functional interactions of three highly conserved proteins:
adipose triglyceride lipase (ATGL, officially PNPLA2), a-b hydro-
lase domain-containing protein 5 (ABHD5, also known as CGI-
58), and perilipin-1 (PLIN1) or perilipin-5 (PLIN5) (Young and
Zechner, 2013). ATGL is responsible for the first and rate-limitingCell Mstep of triacylglycerol hydrolysis in adipocytes, skeletal muscle,
and heart. ABHD5 is a critical upstream regulator of ATGL that
potently increases the lipase activity of ATGL and, possibly,
other lipases (Lass et al., 2006). Importantly, human mutations
of ATGL and ABHD5 lead to an overlapping spectrum of dis-
eases involving ectopic neutral lipid accumulation in several
tissues (Caux et al., 2004; Fischer et al., 2007; Reilich et al.,
2011; Schweiger et al., 2009).
Much of our understanding of acute lipolytic control derives
from experiments in adipocytes, wherein lipolysis is manipulated
by signals that converge on the cyclic AMP/protein kinase A
(PKA) signaling pathway. In adipocytes, PLIN1 is an LD scaffold
that is thought to be the major locus of lipolysis control.
Under basal conditions, PLIN1 suppresses lipolysis by binding
ABHD5, thereby preventing its activation of ATGL (Gandotra
et al., 2011; Granneman et al., 2009a; Subramanian et al.,
2004). Phosphorylation of PLIN1 by PKA simultaneously re-
leases ABHD5, which activates ATGL and recruits phosphory-
lated hormone-sensitive lipase (HSL) to the LD surface (Granne-
man et al., 2009a; Miyoshi et al., 2006). Currently, PKA-mediated
signaling is the only known means of rapidly (seconds to mi-
nutes) activating adipocyte lipolysis. ABHD5 has also been impli-
cated in intracellular lipolysis in tissues, such as skeletal muscle
and heart, which use fatty acids internally as metabolic fuels. In
these cells PLIN5 binds ABHD5 and suppresses basal and stim-
ulated lipolysis (Pollak et al., 2015; Wolins et al., 2006); however,
the regulation of ABHD5 by PLIN5 is poorly understood and
might involvemechanisms that are independent of PKA (Granne-
man et al., 2009b).
To develop novel probes of intracellular lipolysis, we devised
an assay that measured the interaction of ABHD5 with PLIN1
or PLIN5 and screened for compounds that would disrupt those
interactions in the absence of PKA activation. We identified com-
pounds that potently disrupted the interaction of ABHD5 with
both PLIN1 and PLIN5 and stimulated lipolysis in fat cells
and muscle. The synthetic compounds were found to be direct
ligands of ABHD5 that rapidly regulated its interactions with
PLIN1 and PLIN5. Use of these ligands in molecular imaging as-
says uncovered a pathway involving the dynamic regulation ofetabolism 22, 851–860, November 3, 2015 ª2015 Elsevier Inc. 851
Figure 1. Identification of Compounds that
Disrupt the Interaction of PLIN1with ABHD5
(A) Structure of the tricyclic thio urea (TTU) SR-
4995 and the sulfonyl piperazine (SPZ) SR-4559.
(B) SR-4995 and SR-4559 blocked the interaction
of PLIN1 with ABHD5 in the luciferase comple-
mentation assay (Binding). Values are means ±
SEM of triplicate determinations, and the experi-
ment was replicated more than five times.
(C) SR-4995 dissociates PLIN1(358–415)-EYFP
from LD-targeted ECFP-ABHD5 in Cos7 cells
within 2 min. Imaging results were replicated nine
times. t, time.ABHD5-PLIN interactions by endogenous long-chain acyl-coen-
zyme A (CoA). These results demonstrate that ABHD5 is subject
to rapid direct allosteric regulation by endogenous and synthetic
ligands and suggest that this property might be exploited for
therapeutic benefit.
RESULTS
High-Throughput Screening Identifies Compounds that
Disrupt the Interaction of ABHD5 with PLIN1 and PLIN5
To develop novel probes of intracellular lipolysis, we devised an
assay for compounds that would inhibit the interaction of ABHD5
with PLIN1 or PLIN5 in the absence of PKA activation. The assay
was based upon luciferase complementation between ABHD5
and PLIN1 or PLIN5 (Granneman et al., 2009a, 2009b; Remy
and Michnick, 2006) (PubChem: 493421 and PubChem:
493057) (Supplemental Experimental Procedures; Tables S1
and S2) and was performed under conditions (no ATP or Mg++)
in which PKA is inactive. Screening of >364,000 compounds
from the NIH chemical library identified five compounds, repre-
senting three independent chemical scaffolds, that inhibited
the interaction of ABHD5 with PLIN1 and PLIN5.
Shown in Figure 1A are representative members of two
scaffolds, thiaza-tricyclo-ureas (TTUs) represented by SR-4995
(compound identifier [CID] 16016685), and sulfonyl piperazines
(SPZs) represented by SR-4559 (CID 2674365). SR-4559 and
SR-4995 prevented binding of ABHD5 to PLIN1 in luciferase
complementation assays, with half maximal inhibitory concen-
trations (IC50s) of 510 ± 60 nM and 200 ± 30 nM (n = 8), respec-
tively (Figure 1B). As expected, compounds were fully active in
preventing the interaction of ABHD5 with mutant PLIN1 lacking
all six PKA sites (Figures S1A and S1B). To independently verify852 Cell Metabolism 22, 851–860, November 3, 2015 ª2015 Elsevier Inc.that compounds directly disrupt the inter-
action of ABHD5 with PLIN1 and confirm
compound efficacy using human pro-
teins, we identified PLIN1(358–415), a
minimal fragment of human PLIN1 (amino
acids 358–415) that binds ABHD5 in Cos7
cells. This fragment lacks PKA phosphor-
ylation sites and localizes to LDs by virtue
of its interaction with ABHD5. In the
resting state, the PLIN1 fragment and
ABHD5 were colocalized on LD surfaces,
and SR-4559 (1 mM final) triggered therelease of the PLIN1 fragment within 1 min of extracellular appli-
cation (Figure 1C; Supplemental Information; Movie S1).
PLIN5 can be phosphorylated by PKA (Pollak et al., 2015);
however, treatment of 3T3-L1 preadipocytes with forskolin/
IBMX (3-isobutyl-1-methyl-xanthine) did not alter the ABHD5-
PLIN5 interaction, as determined by fluorescence resonance
energy transfer (FRET), in contrast to the disruption of the
ABHD5-PLIN1 interaction (Figure S1C). Importantly, in brown
adipocytes, SR-4995 rapidly dissociated complexes of ABHD5
and PLIN5 (Figure S1D), as well as complexes of ABHD5 and
a PLIN5 fragment (amino acids 360–417) that lacks PKA sites
(Figure S1E).
Compounds Rapidly Stimulate Lipolysis in Adipocytes
andMuscle without Activating Phosphorylation of PLIN1
or HSL
Next, we tested the effects of compounds on lipolysis in cultured
brown adipocytes. We found that SR-4995 and SR-4559
stimulated lipolysis with half maximal effective concentrations
(EC50s) of about 4 mM and produced maximal lipolytic rates
that were >75% of those produced by isoproterenol, a full
b-adrenergic receptor agonist (Figure 2A). We also examined
the temporal relation between compound application and
intracellular fatty acid mobilization in live cells by fluorescence
microscopy. In this assay, mobilized fatty acids trigger the trans-
location of enhanced yellow fluorescent protein (EYFP)-tagged
SRC1 to the ligand-binding domain (LBD) of PPARa, which has
been targeted to the LD surface by fusion to PLIN1 (Figure 2B)
(Mottillo et al., 2012, 2014b). We found that compounds trig-
gered lipolysis within 3 min, on a time frame similar to that of
the dissociation of PLIN1-ABHD5 complexes (Supplemental
Information; Movie S2).
Figure 2. TTU and SPZ Ligands Activate
Brown Adipocyte Lipolysis
(A) SR-4995 and SR-4559 stimulate lipolysis with
an EC50 of 4–7 mM. In the same assay, isoproter-
enol (ISO; 1 mM) released 28–32 nmol free fatty
acids (FFA) per hour. Values are means ± SEM of
triplicate determinations, and the experiment was
replicated more than five times.
(B) SR-4559 rapidly stimulates adipocyte lipolysis,
indicated by fluorescence increase on LDs (ar-
rows). Imaging results were replicated four times.
t, time.
(C and D) Stimulation of lipolysis by SR-4995 and
SR-4559 does not involve PKA-mediated phos-
phorylation. Brown adipocytes were treated with
isoproterenol (10 nM), SR-4995, or SR-4559
(10 mM) for 30 min before determining fatty acid
release (C) and phosphorylation of PLIN1 and HSL
with phospho-specific antibodies (D). Values are
means ± SEM of triplicate wells. Experiments
shown were replicated twice.
(E and F) SR-4995 stimulates lipolysis in mouse
diaphragm ex vivo (E) without affecting phos-
phorylation of HSL (F). Values are means ± SEM;
n = 6. ***p < 0.001.As mentioned earlier, activation of cyclic AMP (cAMP)-depen-
dent PKA is the only known mechanism for rapid activation of
adipocyte lipolysis. As expected, stimulation of lipolysis by
the b-adrenergic agonist isoproterenol led to strong phosphory-
lation of PLIN1 and HSL, as determined by phospho-specific
antibodies. In contrast, equally effective concentrations of
SR-4995 and SR-4559 triggered lipolysis without activating
phosphorylation of either HSL or PLIN1 (Figures 2C and 2D).
The similar efficacy of compounds in disrupting complexes of
ABHD5 with PLIN1 or PLIN5 suggested that these agents might
stimulate lipolysis in muscle, where PLIN5 is present but PLIN1 is
not. We found that SR-4995 (10 mM) and isoproterenol (10 mM)
were equally effective in stimulating lipolysis in mouse dia-
phragm muscle ex vivo (Figure 2E). Importantly, SR-4995 stimu-
lated muscle lipolysis in the absence of HSL phosphorylation,
unlike isoproterenol (Figure 2F).
Compound Stimulation of Lipolysis Requires ABHD5
and ATGL
To verify the mechanism of compound action, we performed
knockdown and rescue experiments with ABHD5. As shown
in Figure 3A, SR-4995 and SR-4559 compounds (10 mM)
increased lipolysis by 7-fold in cultured brown adipocytes,
and stable knockdown of ABHD5 by lentiviral short hairpin
RNA (shRNA) (Figure 3A, insert) abolished the ability of com-
pounds to stimulate lipolysis. We transduced the knockdown
cell line with a doxycycline-inducible ABHD5 construct that is
resistant to the viral shRNA (Figure 3B). When tested in knock-
down adipocytes, compounds were completely inactive in theCell Metabolism 22, 851–860,absence of doxycycline, and the activity
induced by isoproterenol was also
reduced by 85%. Reinstatement of
ABHD5 expression with doxycycline
restored the efficacy of the TTU andSPZ agonists, as well as isoproterenol, establishing that stimu-
lation of lipolysis by compounds requires ABHD5. Compounds
SR-4995 and SR-4559 stimulated lipolysis in freshly isolated
mouse white adipocytes, and this effect was eliminated by
adipocyte-specific knockout of ATGL (Figure 3C), the major
lipase target of ABHD5 in adipocytes. We confirmed that
ABHD5 potently increases the activity of ATGL against artificial
LDs in vitro (Figure 3D) and found that SR-4995 and SR-4559
did not modify this effect. These observations indicate that the
compounds act by relieving inhibition by PLIN proteins and
that binding of compounds, per se, does not increase the ability
of ABHD5 to activate ATGL.
Compounds Directly Bind ABHD5
In theory, compounds that dissociate complexes could bind
either ABHD5 or PLIN proteins; however, the similar potency
of compounds in preventing formation of complexes of
ABHD5 with PLIN1 or PLIN5 (Figures S1C and S2) suggested
that ABHD5 was the likely target. To determine whether
ABHD5 was the direct binding target, we made use of an affin-
ity probe, NBD-HE-HP, that was previously shown to covalently
modify ABHD5 (Birner-Gruenberger and Hermetter, 2007). As
shown in Figure 4A, the NBD-HE-HP affinity tag covalently
modified ABHD5 in transfected Cos7 cells, and this labeling
was blocked by co-incubation with TTU and SPZ ligands
(50 mM). Importantly, SR-4995 blocked NBD-HE-HP binding
to ABHD5, with a potency nearly identical to that observed
for disrupting the interaction of ABHD5 with PLIN1 (Figures
1B and 4B). As expected (Birner-Gruenberger and Hermetter,November 3, 2015 ª2015 Elsevier Inc. 853
Figure 3. Stimulation of Lipolysis by SR-
4995 and SR-4559 Requires ABHD5 and
ATGL
(A) Stable knockdown of ABHD5 by shRNA (insert)
eliminated stimulation of lipolysis by SR-4995 and
SR-4559 (10 mM). ***p < 0.001.
(B) Rescue of ABHD5 expression restores com-
pound efficacy. In the absence of doxycycline
(Dox), SR-4995 and SR-4559 were inactive, and
the efficacy of isoproterenol (Iso) was severely
reduced. Induction of ABHD5 by doxycycline
reinstated SR-4995 and SR-4559 activity and
increased responsiveness to isoproterenol by
5-fold. Values for experiments in (A and B) are
means ± SEM of three independent experiments.
(C) SR-4995 and SR-4559 stimulated lipolysis in
isolated white adipocytes, and this effect was
abolished by adipocyte-specific knockout of
ATGL (ATGL-KO). Values are means ± SEM of an
experiment performed in triplicate and replicated
twice. ***p < 0.001. FFA, free fatty acids.
(D) Compounds do not augment the ability of
ABHD5 to stimulate lipase activity of ATGL using
artificial substrates in vitro. Values are means ±
SEM of a representative experiment that was
repeated three times.2007), the NBD-HE-HP affinity probe also labeled HSL ex-
pressed in transfected Cos7 cells; however, SR-4995 did not
block NBD-HE-HP binding to HSL (Figure 4B) or ATGL (Fig-
ure S3), demonstrating the specificity of this ligand for binding
to ABHD5.
NBD-HE-HP was developed as an active-site affinity label
of serine hydrolases; however, because ABHD5 lacks the
conserved catalytic serine seen in related a-b hydrolases
(Caux et al., 2004; Schweiger et al., 2009; Yen and Farese,
2006), we reasoned that the site of modification and ligand in-
teractions likely involves a novel binding domain. To determine
the site of protein modification, we subjected purified NBD-HE-
HP-labeled and unlabeled ABHD5 to liquid chromatography-
tandem mass spectrometry (LC-MS/MS) analysis and observed
ten unique spectra demonstrating that Y330 is modified by the
affinity ligand. Shown in Figure 4C are representative MS-2
spectra of peptide Thr321-Lys342 from unmodified (Figure 4C,
top) and NBD-HE-HP-labeled (Figure 4C, bottom) ABHD5. The
mass-to-charge ratio (m/z) difference of b9 and b10 ions in un-
labeled and labeled ABHD5 unambiguously identified Y330 as
the site of NBD-HE-HP modification, which was confirmed by
the mass shift of the remaining b ions. As expected, mutation
of Y330 to alanine or phenylalanine prevented tagging by
NBD-HE-HP (Figure 4D). Mutation of Y330 to alanine or phenyl-
alanine, however, did not affect the ability of ABHD5 to pro-
mote lipolysis or to interact with PLIN1 (data not shown). These
data indicate that the SPZ and TTU ligands directly target
ABHD5 and that the binding pocket overlaps with that occu-
pied by NBD-HE-HP. The binding pocket likely includes the
highly conserved Y330, since it is directly modified by NBD-854 Cell Metabolism 22, 851–860, November 3, 2015 ª2015 ElsevierHE-HP, but this residue is not critical for binding of SR-4995
or SR-4559.
Synthetic Ligands and Long-Chain Acyl-CoA Converge
to Regulate the Dynamic Interaction of ABHD5with PLIN
Proteins
The demonstration that ABHD5 is sensitive to synthetic ligands
exposes a new locus of lipolysis control that bypasses the PKA
signaling pathway and raises the question of whether synthetic
ABHD5 ligands exploit binding sites used by endogenous
ligands. We previously reported that external application of a
mono-unsaturated fatty acid, oleic acid (OA), increases the inter-
action of ABHD5 with PLIN5 (Granneman et al., 2009b) in trans-
fected 293T cells, and this effect likely involved synthesis of long-
chain acyl-CoA. To assess the dynamic interaction of ABHD5
with PLIN proteins, we identified a minimal fragment of PLIN5,
amino acids 384–417, that binds ABHD5 but is not otherwise tar-
geted to LDs. The release of PLIN5(384–417) from LDs contain-
ing ABHD5 is a robust and dynamic assay that can be monitored
by FRET in the whole cells or by the ratio of PLIN5/ABHD5 fluo-
rescence at the LD surface. As shown in Figure 5A andMovie S3,
SR-4995 rapidly dissociated complexes of enhanced cyan fluo-
rescent protein (ECFP)-ABHD5 and PLIN5(384–417)-EYFP and
application of OA reassociated complexes within 2 min. Similar
results were obtained with palmitic acid (Figure 5B), indicating
that the effect was not specific to monounsaturated fatty acids.
The effect of OA was concentration dependent and exhibited
clear evidence of saturation (Figures 5C and 5D). Importantly,
the effect of OA on complex formation could be readily over-
come by a higher concentration of SR-4995 (Figures 5E andInc.
Figure 4. NBD-HE-HP Affinity Ligand Identifies ABHD5 as the Target of SR-4995 and SR-4559
(A) Cos7 cells expressing ABHD5 were labeled with NBD-HE-HP (50 mM) in the presence of DMSO, SR-4995, or SR-4559 (50 mM) for the indicated times. Cellular
proteins were resolved by SDS-PAGE, and labeled proteins were imaged by laser-scanning fluorometry.
(B) NBD-HE-HP labeled both HSL and ABHD5 in transfected Cos7 cells, and SR-4995 potently blocked labeling of ABHD5 but not HSL. Experiments in (A and B)
were each performed twice with the same result.
(C) MS of NBD-HE-HP-labeled ABHD5 identifies Y330 as the amino acid covalently modified by the affinity ligand.
(D) Mutation of Y330 to alanine (A) or phenylalanine (F) eliminates covalent modification of ABHD5 by NBD-HE-HP. Non, nontransfected cells. The experiment
was repeated three times for the Y330F mutation and twice for the Y330A mutation.5F). Similar results were obtained using tagged human ABHD5
and human PLIN1(358–417) (Figure S4). Together, these obser-
vations indicate that synthetic ABHD5 ligands and long-chain
fatty acids, or a closely associated metabolite, converge on a
common binding site in ABHD5 that dynamically regulates its as-
sociation with PLIN proteins.
Based on previous work (Granneman et al., 2009b), we hy-
pothesized that long-chain acyl-CoA was a likely physiological
ligand of ABHD5. Consistent with this hypothesis, we found
that OA rapidly promoted the association of ABHD5 and
PLIN5(384–417) in Cos7 cells cultured in the absence of OA
supplementation (Figure 6A). As a control, we examined the ef-
fects of the ethyl ester of OA (OAEE), which cannot directly
form oleoyl-CoA without prior intracellular hydrolysis. We found
that OAEE failed to trigger formation of ABHD5/PLIN5 com-
plexes. Furthermore, OA, but not OAEE, rapidly reversed com-
pound-induced dissociation of ABHD5/PLIN5 complexes (Fig-
ure 6B). OA rapidly reversed compound-induced dissociation
in the presence of OAEE, indicating that the tested concentra-
tions of OAEE are not toxic to COS7 cells (Figure S5). As ex-
pected, treatment of intact cells with OA or palmitic acid
(50 mM) suppressed NBD-HE-HP labeling of ABHD5 in trans-Cell Mfected Cos7 cells (Figure 6C). Importantly, we found that
oleoyl-CoA, but not OA, effectively blocked NBD-HE-HP label-
ing of purified ABHD5 (Figure 6D), directly demonstrating that
oleoyl-CoA, derived from OA, is an endogenous ligand of
ABHD5.
DISCUSSION
The canonical pathway for rapid regulation of lipolysis in adipo-
cytes involves integration of extracellular signals and PKA-
dependent phosphorylation of the key lipolytic effectors PLIN1
and HSL (Granneman et al., 2009a; Miyoshi et al., 2006, 2007).
Unlike white adipocytes, which export mobilized fatty acids in
response to external signals, other tissues, including muscle
and brown adipose tissue, mobilize fatty acids from intracellular
LDs for oxidation in situ. Thus, it might be expected that
additional mechanisms exist for balancing fatty acid supply
with demand that are independent of transmembrane signaling.
Using a novel protein interaction assay, we discovered com-
pounds that potently disrupt the interaction of ABHD5 with
PLIN1 or PLIN5. These synthetic ligands rapidly stimulated lipol-
ysis in adipocytes (white and brown) and muscle in the absenceetabolism 22, 851–860, November 3, 2015 ª2015 Elsevier Inc. 855
Figure 5. Long-Chain Fatty Acids and Syn-
thetic Compounds Converge on a Common
Mechanism to Dynamically Regulate Inter-
action of ABHD5 and PLIN5
(A) Cos7 cells expressing ECFP-ABHD5 and
PLIN5(384–417)-EYFP were treated with SR-4995
(25 mM) at time = 0 and then exposed to OA
(100 mM) or BSA carrier 10 min later. OA treatment
reversed the effects of SR 4995 and rapidly pro-
moted reappearance of ABHD5/PLIN5 com-
plexes. Values are means ± SEM; n = 15–16 cells.
(B) Palmitic acid (PA) reverses dissociation of
ABHD5-PLIIN5 complexes induced by SR-4995
(25 mm). Values are means ± SEM; n = 10–12 cells.
(C and D) As shown in (C), cells were exposed to
increasing concentrations of OA, demonstrating
that the effect of OA is concentration dependent
and saturable. (D) Values are means ± SEM; n = 6
cells.
(E) The effects of SR-4995 and OA are fully
reversible. Association/dissociation kinetics were
monitored by the ratio of PLIN5 fluorescence
(pseudocolored green; G) to ABHD5 fluores-
cence (pseudocolored red; R) on LDs. ABHD5-
PLIN5(384–417) complexes were dissociated by
10 mM SR-4995, reassociated by 200 mM OA, and
then dissociated again by a higher concentration
of SR-4995. The experiment was replicated three
times, with similar results.
(F) Merged confocal images of PLIN5 and ABHD5
channels demonstrating the reversible dissocia-
tion/association kinetics. t, time.of PKA-mediated phosphorylation of PLIN1 and HSL. Knock-
down and rescue experiments demonstrated that compound
activation of lipolysis is mediated by ABHD5 and requires
ATGL. These results demonstrated that the synthetic com-
pounds bypass receptor-mediated activation and directly disso-
ciate ABHD5 from its inhibitory regulators, PLIN1 and PLIN5.
By taking advantage of the NBD-HE-HP affinity label, we were
able to show that our synthetic ligands directly bind ABHD5. MS
of purified ABHD5 demonstrated that the docking site for NBD-
HE-HP includes Y330, which lies within the highly conserved
HYVYAD sequence of ABHD5. Although this sequence loosely
resembles the H4XD (where X is any amino acid) motif observed
in numerous hydrolases and acyl-transferases (Heath and Rock,
1998; Lewin et al., 1999), there are no data indicating involve-
ment of this sequence in any enzymatic activity. However, the
observation that SPZ and TTU ligands similarly disrupted
ABHD5/PLIN complexes composed of human ormouse proteins
indicates that the binding pocket is well conserved and raised
the possibility that endogenous ligands might bind to ABHD5
in a manner that modulates its interactions with PLIN proteins.
Previous work showed that treating cells with OA for 1 to 2 hr
increases the interaction of ABHD5 and PLIN5, and this effect is
inhibited by blocking long-chain acyl-CoA synthesis with triacsin
C (Granneman et al., 2009b). The discovery of synthetic ABHD5856 Cell Metabolism 22, 851–860, November 3, 2015 ª2015 Elsevier Inc.ligands and the development of fluores-
cent imaging tools allowed us to explore
the physiological significance of ligand-
regulated interactions between ABHD5and PLIN proteins with high temporal and spatial resolution.
We found that OA treatment rapidly reversed complex dissocia-
tion that was induced by synthetic ligands. This effect was satu-
rable and was readily overcome by higher concentrations of
synthetic ligand. Treatment of live cells with OA or synthetic
ligands effectively disrupted ABHD5 labeling by NBD-HE-HP,
and competition binding experiments with purified ABHD5
demonstrated that oleoyl-CoA is a physiological metabolite
that binds ABHD5. These results strongly indicate that ABHD5
contains a common binding site for synthetic and endogenous
ligands. Furthermore, these ligands appear to be potent allo-
steric modulators that disrupt or promote the interaction of
ABHD5 with PLIN proteins.
Physiologically, the regulation of ABHD5-PLIN interactions
by long-chain acyl-CoA provides an elegant negative feedback
mechanism whereby fatty acid production is closely linked to
its metabolism. This rapid regulation may be especially impor-
tant in coupling fatty acid mobilization and oxidation in muscle
and brown adipose tissue, where LDs and mitochondria are
very closely associated and PLIN5 likely plays a role in forming
a ‘‘metabolic synapse.’’ PLIN5 is targeted to the LD surface
that apposes mitochondria, where it assembles the core lipolytic
machinery by separately binding both ABHD5 and ATGL (Gran-
neman et al., 2011; Kimmel and Sztalryd, 2014; Wang et al.,
Figure 6. Long-Chain Acyl-CoAs Are ABHD5 Ligands and Mediate
the Effects of OA
(A) OA, but not OAEE, promotes the association of ABHD5 and PLIN5. Cos7
cells were transfected with fluorescently tagged ABHD5 and PLIN5 constructs
and cultured overnight without OA supplementation. Cells were then exposed
to OA (300 mM) or OAEE (300 mM).
(B) OA, but not OAEE, reverses compound-induced complex dissociation.
Cos7 cells expressing fluorescently tagged ABHD5 and PLIN5 constructs
were treated with SR-4995 (10 mM) at time = 0 and then exposed to OA
(300 mM) or OAEE (300 mM) 5min later. For (A and B), values are means ± SEM;
n = 10–12 cells.
(C) Treatment of Cos7 cells with OA (400 mM) or palmitic acid (PA, 400 mM)
inhibited NBD-HE-HP labeling of ABHD5.
(D) NBD-HE-HP labeling of purified ABHD5 was inhibited by oleoyl-CoA
(O-CoA, 50 mM), but not OA (50 mM). Experiments were performed at least two
times with similar results.2011). Long-chain acyl-CoA synthase 1 (ACSL1), which acti-
vates fatty acids released from LDs, resides on the outer mito-
chondrial membrane and is well situated to both direct fatty
acids toward oxidation (Ellis et al., 2010, 2011) and modulate
fatty acid supply via feedback inhibition that could involve
ABHD5, ATGL, and HSL (Nagy et al., 2014; Severson and Hurley,
1984). SR-4995 did not block NBD-HE-HP labeling of HSL or
ATGL, indicating that this activator does not affect lipolysis by
direct interaction with these lipases (for example, by relieving
acyl-CoA inhibition). Furthermore, synthetic compounds are
inactive in the presence of HSL and ATGL if ABHD5 is absent.
The precise mechanism by which ABHD5 activates lipolysis
is not understood. Our synthetic ligands did not promote the
ATGL-activating properties of ABHD5 in biochemical assays
that lacked PLIN proteins, indicating that the activation of lipol-
ysis in intact cells involves the release of inhibition produced
by PLIN binding. Conversely, our results indicate that long-chain
acyl-CoA can suppress lipolysis, in part, by promoting the
sequestration of ABHD5 by PLIN proteins. Whether endogenous
ligands exist that can dissociate ABHD5/PLIN complexes, as
do our synthetic compounds, is currently under investigation.
ABHD5 has no confirmed enzymatic activity, and the simplestCell Mmodel for activation entails direct allosteric activation of ATGL
(Lass et al., 2006). It should be noted, however, that ABHD5
appears to activate lipases other than ATGL (Zierler et al.,
2014), and it is conceivable that stimulation of lipolysis is medi-
ated by other effects that ABHD5 exerts on LD surfaces. Regard-
less, the synthetic ABHD5 ligands we have discovered will likely
provide new insights into ATGL-dependent and independent
functions of ABHD5.
Finally, might ABHD5 ligands be developed into novel thera-
peutic entities? In general terms, the mass of triacylglycerol,
which accumulates in adipose tissues, reflects the balance be-
tween energy storage and mobilization, and it is well established
that persistent activation of adipocyte lipolysis by b3-adrenergic
receptors triggers thermogenic responses that have potent anti-
obesity and anti-diabetes properties in rodent models (Arch,
2002). Given that fatty acids are necessary and sufficient for
brown adipocyte thermogenesis (Fedorenko et al., 2012; Guerra
et al., 1998; Nicholls, 2006) and adipose-tissue-specific overex-
pression of ATGL improves metabolic status of mice challenged
with a high-fat diet (Ahmadian et al., 2009), ABHD5 ligands might
provide a more direct means of promoting fat catabolism in
brown and white adipose tissues that overcomes limitations
associated with surface receptor expression (Arch, 2002). In
addition, ABHD5 was recently shown to be a potent tumor sup-
pressor in colorectal cancer (Ou et al., 2014). It has been pro-
posed that loss of ABHD5 function promotes tumor invasiveness
by reducing fatty acid oxidation and enhancing the production of
growth-promoting metabolites from glycolysis. It would be pre-
dicted from these observations that activators of ABHD5, like
those described here, might delay or prevent tumor progression
by promoting oxidative metabolism.
In summary, high-throughput compound screening identified
ligands of ABHD5 that stimulate lipolysis in adipocytes and
muscle, bypassing canonical PKA-dependent signaling. The
synthetic ligands exposed an endogenous feedback pathway
whereby long-chain acyl-CoA rapidly modulated the interaction
of ABHD5 with PLIN proteins. Our results demonstrate that
ABHD5 is a ligand-regulated lipase activator, providing a foun-
dation for the development of a new class of synthetic lipolysis
modulators.EXPERIMENTAL PROCEDURES
High-Throughput Compound Screening
Luciferase complementation constructs were generated as previously
described (Granneman et al., 2009a, 2009b, 2011), and proteins were pro-
duced in 293T or Sf9 cells. High-throughput compound screening was per-
formed by the Molecular Screening Center at the Scripps Research Institute
in Jupiter, Florida. The assays and primary screeningmethods and their results
are detailed in PubChem BioAssay: 493241 (ABHD5/PLIN5) and PubChem
BioAssay: 493057 (ABHD5/PLIN1). The stepwise protocol used for the protein
complementation high-throughput screening (HTS) assays, screening strat-
egy, and confirmatory counterscreening in the ABHD5/PLIN1-5 screening
campaign are detailed in the Supplemental Experimental Procedures and in
Tables S1 and S2.
Molecular and Biochemical Techniques for Secondary Analyses
Cellular lysates were prepared from transfected 293T cells (Granneman et al.,
2009a, 2009b), and complementation assays were performed in 96-well
plates using 50 ml of each lysate and 1 ml of compounds dissolved in
DMSO or DMSO vehicle. Luciferase activity was determined after incubationetabolism 22, 851–860, November 3, 2015 ª2015 Elsevier Inc. 857
for 4 hr at room temperature. Immunoblotting was performed as previously
described (Mottillo et al., 2012). In vitro lipolysis assays were performed
using ABHD5 purified from Sf9 cells and ATGL overexpressed in Cos7
cells, as detailed previously (Schweiger et al., 2014). Cloning and mutagen-
esis were performed using PCR, and all constructs were confirmed by
sequencing.
Analysis of Lipolysis in Brown Adipocytes and Muscle
Immortalized brown adipocytes were seeded in 96-well plates and differen-
tiated as described previously (Mottillo et al., 2012). At 3–4 days after induc-
tion of differentiation, cells were washed and placed in HEPES-buffered
Krebs-Ringer buffer containing 1% BSA (KRBB) and treated with DMSO
(vehicle) or activators at concentrations specified in the figures. Results are
reported as fatty acid efflux per well, each containing 76,000 cells. Accu-
mulated fatty acids were determined using Wako kits (Wako Pure Chemicals
Industries) adapted to fluorescence detection with Amplex Red, as described
previously (Mottillo et al., 2012). Whole mouse diaphragms were removed,
washed with PBS, divided into 20-mg segments, and incubated in 500 ml
of KRBB in the presence of vehicle, SR-4995, or isoproterenol at the indi-
cated concentration. Aliquots (30 ml) were removed after 1, 2, and 3 hr and
assayed for fatty acid release, as detailed earlier. Immunoblotting for
PLIN1, HSL, and ABHD5 was performed as previously described (Granne-
man et al., 2009a, 2011). Phospho-HSL and phospho-PLIN1 antibodies
were purchased from Cell Signaling Technology (#4126) and Vala Sciences
(#4856), respectively.
Stable Knockdown and Inducible Rescue of ABHD5 in Brown
Adipocytes
Lentiviral shRNA to Abhd5 was created from a plasmid purchased from Sigma
(TRCN0000032737 NM_026179.1-1063s1c1) and used to stably transduce
mouse brown adipocytes. Knockdown was confirmed by immunoblotting of
differentiated adipocytes. To create an inducible rescue cell line, we mutated
the DNA sequence targeted by the shRNA while maintaining the wild-type
amino acid sequence of ABHD5, and we tagged the construct with mCherry.
Doxycycline-inducible expression was achieved by transferring the shRNA-
resistant construct into pINDUCER20 (Meerbrey et al., 2011), and the resulting
lentivirus was used to infect the brown adipocytes in which endogenous
ABHD5 was stably knocked down.
Induced Knockout of ATGL in Mouse Adipocytes
Induced knockout of ATGL and analysis of adipocyte lipolysis were
performed as described previously (Mottillo et al., 2014a). Briefly, B6N.129S-
Pnpla2tm1Eek, B6N.129S-Tg(Adipoq-CreERT2)tm1Jgra double transgenic mice
or single transgenic B6N.129S-Pnpla2tm1Eek (control) mice were treated with
tamoxifen 1 week prior to adipocyte isolation and analysis of fatty acid release.
Assays were performed in 200 ml of KRBB using 5% packed cell volume
(10,000 cells).
Imaging Compound Action in Live Cells
DNA constructs encoding human and mouse ABHD5 and PLIN proteins (and
fragments) were amplified by PCR and cloned into the expression vectors
ECFP-C1 and EYFP-N1, respectively. Cos7 cells were plated onto coverslips
and transfected and loaded with OA, as previously described (Granneman
et al., 2009a, 2011). Prior to imaging, cells were washed once in KRBB and
imaged at room temperature in KRBB. Compounds were added as 103 or
203 solutions dissolved in KRBB. Ratiometric imaging, including FRET, was
performed using IPlabs software, as previously described (Granneman et al.,
2009a, 2011). FRET images of individual cells were imported into ImageJ to
determine the average net FRET values for each frame, which were then
normalized to the mean value of three baseline images. For imaging of fatty
acid production in live cells, we created a brown adipocyte cell line that ex-
presses a fatty acid reporter system (Mottillo et al., 2014b) under the control
of a doxycycline-sensitive promoter. In this system, PLIN1 is fused to the
PPARa LBD, thus targeting the fatty-acid-sensing domain of PPARa to LDs.
Mobilized fatty acids bound by the PPARa LBD are detected by the accumu-
lation of EYFP-tagged SRC1 coactivator binding domain at the LD surface. All
imaging experiments were performed on more than three different coverslips
and replicated in independent transfections.858 Cell Metabolism 22, 851–860, November 3, 2015 ª2015 ElsevierCovalent Labeling of ABHD5 with NBD-HE-HP and MS of Labeled
Peptides
NBD-HE-HP affinity label was synthesized and purified as described previ-
ously (Birner-Gruenberger and Hermetter, 2007; Schmidinger et al., 2005).
Cos7 cells transfected with PLIN1 and wild-type or mutant ABHD5 were lipid
loaded overnight with 200 mM OA. One day after transfection, cells were
labeled with 50 mM NBD in serum-free DMEM for 1 hr at 37C. Cells were
rinsed with PBS, and protein-matched aliquots of cell lysates were separated
by SDS-PAGE. Two gels were run in parallel, one for fluorescent scanning and
one for immunoblot detection of ABHD5. Gels for scanning were fixed (45%
MeOH, 10% acetic acid) and then visualized on a Typhoon 9410 Variable
Mode Imager (GE Healthcare; excitation, 488 nm; emission, 520 nm).
LC-MS/MS Characterization of NBD-HE-HP-Labeled ABHD5
293T cells transfected with His-tagged ABHD5 were labeled with NBD-HE-HP
in serum-free DMEM for 3 hr at 37C. His-tagged ABHD5 was partially purified
by His60 Ni2+ Superflow Resin column chromatography (Clontech Labora-
tories), as described by the manufacturer. Labeled ABHD5 was further
resolved by SDS-PAGE, and gel bands containing labeled ABHD5 were sub-
jected to LC/MS analysis (details are given in the Supplemental Experimental
Procedures).
Effect of OA and Oleoyl-CoA on NBD-HE-HP Labeling of ABHD5
ABHD5-transfected COS7 cells were incubated in serum-free medium for
2–3 hr to allow clearance of remaining OA from overnight lipid loading.
400 mM of OA or 400 mM of palmitic acid (complexed to BSA) was then added
2 min prior to labeling with 50 mM of NBD-HE-HP. Cells were allowed to label
for 2 hr at 37C. Parallel gels were run for scanning and for ABHD5 immuno-
blotting. Similar results were obtained when ABHD5 was co-transfected with
Plin5 (data not shown). For cell-free labeling of ABHD5, His-tagged ABHD5
was expressed in High-Five insect cells and purified by His60 Ni2+ Superflow
Resin column chromatography (Clontech). Coomassie staining of SDS-PAGE
gels indicated that ABHD5-His protein was approximately 50% pure (data not
shown). Purified ABHD5 was resuspended in 100 mM of potassium phos-
phate buffer (pH 7.0) containing artificial LDs (phosphatidylcholine:phospha-
tidylinositol [PC:PI], 3:1) and was pretreated for 15 min with 50 mM of OA or
50 mM of oleoyl-CoA (Avanti) prior to the addition of 50 mM of NBD-HE-HP.
All ligands were dissolved in DMSO. Labeling then proceeded for 2 hr at
37C, samples were separated by SDS-PAGE, and gels were scanned as
described earlier.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, two tables, and three movies and can be found with this article
online at http://dx.doi.org/10.1016/j.cmet.2015.08.023.
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